NASDAQ$SIGA

SIGA Technologies, Inc · Q4 2019 earnings

Q4 2019 earnings · · Investor relations

Briefing

SIGA Technologies reported financial results for fiscal year 2019.

SIGA Technologies reported a revenue of approximately $27 million and an operating loss of approximately $2 million for the year ended December 31, 2019. The company's cash and cash equivalents were approximately $161 million at the end of the year. SIGA also announced product delivery expectations for oral TPOXX® and a $50 million share repurchase program.

  • Revenue for the year ended December 31, 2019, was approximately $27 million.
  • Operating loss for the year was approximately $2 million.
  • Net loss per share was $0.15 per diluted share for the year.
  • Cash and cash equivalents were approximately $161 million at December 31, 2019.

Headline financials

Total Revenue

$4.26M

Previous: $1.57M+171.8%
EPS (adj)

-$0.06

Previous: -$4.64+98.7%
Capital Expenditures

$29.1K

Previous: $102K-71.6%
Free Cash Flow

-$14.3M

Previous: -$3.69M-287.0%
Net Income

-$7.24M

Previous: $52.4M-113.8%
Operating Income

-$2.32M

Previous: -$5.54M+58.1%
Gross Profit

$210K

Previous: -$1.51M+113.9%
Cash & Equivalents

$65.2M

Previous: $101M-35.2%
Total Assets

$199M

Previous: $203M-2.4%
Stock-Based Comp

$397K

Previous: $407K-2.5%

Revenue & EPS history

SIGA Technologies · Revenue · Quarterly

$4.26M

Q4 2019+171.8%vs Q4 2018

Revenue by segment

SIGA Technologies · $26.7M total across 2 segments · Q4 2019

  • R&D Revenues
    $15.6M
  • Product Sales
    $11.2M

Forward guidance

SIGA expects the near-term exercise of procurement options by BARDA under the 19C BARDA Contract worth a total of approximately $101 million for the procurement of 363,070 courses of oral TPOXX® (tecovirimat).

Tailwinds

  • Near-term exercise of procurement options by BARDA expected.
  • Total of approximately $101 million for the procurement of 363,070 courses of oral TPOXX®.
  • Deliveries of oral TPOXX® to the Strategic National Stockpile (SNS) are expected to start in the second quarter of 2020.
  • Approximately $101 million of oral TPOXX® courses are expected to be delivered to the SNS by April 2021.
  • The 19C BARDA Contract would have up to $414 million of procurement-related options remaining for future exercise.

Headwinds

  • The timing and actual number of shares repurchased will depend on various factors.
  • Exercise of procurement options under government contracts will affect share repurchases.
  • Alternative opportunities for strategic uses of cash will affect share repurchases.
  • The stock price of the Company’s common stock will affect share repurchases.
  • Prior to executing any repurchases under this program, the Company’s current term loan would need to be amended or fully repaid.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q4 2019

Historical avgQ4 2019

-0.2%

Avg return

Earnings day

+0.5%

Avg return

5 days after

+2.4%

Avg return

30 days after

41%

26 / 64 earnings

Positive

+31.9%

Q4 2023

Best reaction

-27.8%

Q1 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+0.4%-5.5%-8.5%
Q4 2025-3.0%-3.4%-22.8%
Q3 2025-20.2%-24.0%-24.1%
Q1 2025+4.4%+9.0%+10.8%
Q4 2024+7.0%+0.5%+6.4%
Q3 2024-1.9%-8.5%-9.8%
Q2 2024-12.8%-14.3%-9.5%
Q1 2024-27.8%-28.2%-26.7%
Q4 2023+31.9%+49.9%+88.3%
Q3 2023-4.4%-2.2%+16.9%
Q2 2023-3.7%-10.0%-21.9%
Q1 2023+5.1%+1.8%-0.7%
Q4 2022-3.8%-7.8%-13.4%
Q3 2022+7.5%+9.8%+1.1%
Q2 2022+27.4%+24.6%-21.0%
Q1 2022+3.6%+4.0%+60.7%
Q4 2021+3.0%+6.6%+22.4%
Q3 2021-0.7%+0.0%+2.8%
Q2 2021-2.9%-4.0%+9.1%
Q1 2021-0.7%-8.4%-10.4%
Q4 2020+1.7%+9.3%+1.2%
Q3 2020+2.0%+3.4%-0.9%
Q2 2020+14.3%+5.5%-1.9%
Q1 2020-1.4%+1.4%+2.9%
Q4 2019+10.4%+0.4%+0.2%
Q3 2019-3.2%-1.8%-19.8%
Q2 2019+0.2%-1.7%+2.7%
Q1 2019+1.5%-1.3%-12.8%
Q4 2018-4.4%-1.6%-6.3%
Q3 2018+8.4%+5.7%+29.1%
Q2 2018+0.3%+7.7%+1.4%
Q1 2018-0.5%+2.4%-3.9%
Q4 2017-0.6%-7.0%-2.3%
Q3 2017+2.8%-1.1%+3.9%
Q2 2017-1.6%-1.6%-1.9%
Q1 2017-0.3%+0.6%-8.0%
Q4 2016-0.6%+0.0%-4.1%
Q3 2016-5.7%+3.8%+54.8%
Q2 2016+4.5%+4.1%+11.4%
Q1 2016+1.1%
Q4 2015+1.1%
Q3 2015+2.4%
Q2 2015-0.9%
Q1 2015+5.7%
Q4 2014-1.3%
Q3 2014-0.7%
Q2 2014-4.9%
Q1 2014-1.4%
Q4 2013-2.7%
Q3 2013-3.5%
Q2 2013-2.8%
Q1 2011-2.4%
Q4 2012-2.5%
Q3 2012+6.5%
Q2 2012+5.3%
Q1 2012+4.5%
Q4 2011-1.4%
Q4 2009-1.4%
Q3 2010-6.1%
Q3 2011-6.1%
Q2 2011-12.0%
Q2 2010-12.0%
Q4 2010-12.0%
Q1 2010-1.4%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro